标准剂量CEOP方案治疗老年非霍奇金淋巴瘤患者的临床观察

 【摘要】　目的　分析标准剂量CEOP方案治疗老年非霍奇金淋巴瘤（NHL）患者的疗效和不良反应。方法　回顾性分析福建省立医院2009年 7月至2011年12月接受标准剂量CEOP方案±利妥昔单抗方案（环磷酰胺750 mg／m2 第1天，长春新碱2 mg 第1天，地塞米松10～15 mg 第1天至第5天，表柔吡星 60～75 mg／m2 第1天，利妥昔单抗 375 mg／m2 第0天，每周期间隔21～28 d）化疗的34例老年NHL患者的临床资料。结果　34例患者完全缓解17例，部分缓解9例，稳定3例，进展5例，总有效率为76.5 %（26／34）。主要不良反应为血液学毒性，Ⅲ～Ⅳ度粒细胞减少发生率为71.4 %（24／34）。结论　采用标准剂量CEOP方案治疗老年NHL疗效较高，心脏毒性较低，治疗耐受性良好，对一般状况良好的患者值得推荐。

Clinical study of standard CEOP regimen in the treatment of elderly non-Hodgkin' s lymphoma patients

【Abstract】　Objective　To study the efficacy and toxicity of standard CEOP regimen in elderly patients with non-Hodgkin's lymphoma (NHL). Methods　The study included 34 previously untreated patients, age 60 to 80 years old, with NHL, through July 2009 to December 2011. The patients with T-cell lyphoma received four to eight cycles of CEOP (cyclophosphamide 750 mg/m2 d1, epirubicin hydrochloride 60-75 mg/m2 d1, vincristine 2mg d1, and dexamethasone 10-15 mg d1-5) every 3-4 weeks. Otherwise, the patient with B-cell lymphoma received R-CEOP, rituximab (375 mg/m2) was administered one day before CEOP. All the patients' clinical materials were collected and used to annalyze the efficacy and toxicity of the CEOP±R regimen. Results　Among these 34 NHL patients 17 cases reached CR, 9 cases reached PR, 3 cases remained SD, and 5 cases appeared PD. The total response rate was 76.5 %（26/34). The major toxicity was bone marrow restraint. The rate of leukocyte decline with Ⅱ to Ⅳ degree was 71.4 % (24/34). Conclusion　Using the standard regimen of CEOP leads to satisfied efficacy of elderly patients with NHL, and the toxcity is tolerant.